Jefferies & Company Reports on United Therapeutics

Jefferies & Company commented on United Therapeutics UTHR in a report released today. In the report, Jefferies was mixed in its assessment of the company. Jefferies writes, "We epxect Ph3 monotherapy study for oral treprostinil (FREEDOM-M) to succeed (data in June); we focus on magnitude of 6MWD improvement to better gauge potential success of FREEDOM-C2 (data in Sept). While statistical significance will support regulatory approval, magnitude of 6MWD improvement will determine commercial potential of oral treprostinil, in our view. Our experts' discussions indicate oral treprostinil to provide a ~35-meter 6MWD improvement in FREEDOM-M (monotherapy); at <30-meter improvement, experts comment that there could be a risk to FREEDOM-C2 (combination therapy data in Sept.)." Jefferies currently has a Hold rating on United Therapeutics and a price target of $60. Shares of UTHR closed at $64.71 on Tuesday, down $0.14 on the day.